GMAB Earnings Prediction
The chart below shows how GMAB performed 10 days before and after its earnings report, based on data from the past quarters. Typically, GMAB sees a +3.58% change in stock price 10 days leading up to the earnings, and a +2.94% change 10 days following the report. On the earnings day itself, the stock moves by +0.50%. This data can give you a slight idea of what to expect for the next quarter's release.
GMAB Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
5.54B
16.78%
2.55%
Gross Margin
95.07%
-2.88%
-1.46%
Operating Margin
38.25%
5.69%
9.91%
Net Margin
22.85%
-49.09%
-12.32%
EPS
19.81
-38.71%
-8.71%
No Data Available
GMAB Earnings Analysis
Genmab A/S ADS Corporation (GMAB.O) Earnings Conference Call
Positive
Impressive Revenue Surge: 1. Strong Revenue Growth: Genmab reported total revenue of over DKK 15 billion for the first nine months of 2024, representing a 29% increase compared to the previous year.
Recurring Revenue Surge: 2. Significant Recurring Revenue Increase: Recurring revenues grew by 37%, driven by strong royalties from DARZALEX, Kesimpta, and the performance of EPKINLY and TIVDAK.
Sales Growth Achievement: 3. EPKINLY Sales Performance: EPKINLY achieved $82 million in net sales globally during Q3, marking a 17% growth in the quarter and $203 million in year-to-date sales.
TIVDAK Sales Momentum: 4. TIVDAK Demand Growth: TIVDAK demonstrated its 12th consecutive quarter of demand growth, achieving $32 million in sales, supported by positive feedback from physicians regarding its efficacy.
Operating Profit Surge: 5. Increased Operating Profit: Genmab reported an operating profit of over DKK 4.5 billion, reflecting a growth of more than 27% despite increased investments in R&D and commercialization efforts.
Negative
Pipeline Program Terminations: 1. Pipeline Discontinuations: Genmab has decided to terminate early-stage clinical programs GEN1047, GEN3017, and Gen1056, as well as halt Phase 3 development for TIVDAK in second line plus head and neck cancer, indicating a strategic shift in focus.
Rising Operating Expenses: 2. Increased Operating Expenses: Total operating expenses rose to approximately DKK 9.9 billion, up 23% year-over-year, primarily driven by R&D investments, which accounted for 74% of total expenses, reflecting a significant financial commitment without immediate returns from the deprioritized programs.
Effective Tax Rate Analysis: 3. High Effective Tax Rate: The company reported a tax expense of around DKK 1.6 billion, resulting in an effective tax rate of 28.1%, which may experience volatility due to ongoing evaluations related to the integration of ProfoundBio operations.
TIVDAK Market Concerns: 4. Limited Patient Population for TIVDAK: The decision to discontinue TIVDAK's Phase 3 trial suggests concerns about the potential market size and patient population, which may limit future revenue opportunities in the head and neck cancer segment.
GEN1042 Development Uncertainty: 5. Uncertain Future for GEN1042: Genmab is still collecting data on GEN1042, with no clear timeline for next steps, indicating potential delays in advancing this program and uncertainty in its future development.
GMAB FAQs
How does GMAB typically perform around its earnings report dates?
Is Genmab A/S (GMAB) Q3 2024 Earnings Conference Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
GMAB Earning Call Sentiment
Genmab A/S (GMAB) Q3 2024 Earnings Conference Call Transcript
1.0x
00:00
00:00
GMAB.O
0.53%Positive
Genmab's strong financial performance, with a 29% revenue increase and positive product sales, outweighs concerns about integration and supply chain risks. The optimistic guidance and strategic focus on Phase 3 programs suggest a positive outlook. Despite no shareholder return plan, the market's reaction is likely to be positive, given the strong earnings and optimistic guidance. The Q&A revealed no major negative sentiment, further supporting a positive stock price movement.
